VIR

SEC source: 0001062993-21-011919 · form4.xml · nonDerivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,001,613

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F2 · ownership.nature: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-067149 · doc4.xml · nonDerivative · entry 1

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,566,266

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

SEC source: 0001062993-21-011644 · form4.xml · nonDerivative · entry 3

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,978

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.

SEC source: 0001062993-21-011644 · form4.xml · nonDerivative · entry 2

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 11,947,269

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F3 · ownership.nature: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-21-011644 · form4.xml · nonDerivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,219,394

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F2 · ownership.nature: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-21-011643 · form4.xml · nonDerivative · entry 4

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,657

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.

F6 · ownership.direct: Shares held directly by Bybee.

SEC source: 0001062993-21-011643 · form4.xml · nonDerivative · entry 3

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,298

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.

F5 · ownership.direct: Shares held directly by Crandell.

SEC source: 0001062993-21-011643 · form4.xml · nonDerivative · entry 2

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 11,947,269

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-21-011643 · form4.xml · nonDerivative · entry 1

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,219,394

F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration.

F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

SEC source: 0001209191-21-065833 · doc4.xml · derivative · entry 4

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,129

Underlying: Common Stock · 5,000 shares

Expires 2029-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-065833 · doc4.xml · nonDerivative · entry 3

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-065833 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,742

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.21 to $35.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-065833 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-065618 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,630

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-065618 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.

SEC source: 0001209191-21-065618 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-063007 · doc4.xml · derivative · entry 3

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,129

Underlying: Common Stock · 5,000 shares

Expires 2029-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-063007 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-063007 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-062707 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,005

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-062707 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.

SEC source: 0001209191-21-062707 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-061384 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-061168 · doc4.xml · nonDerivative · entry 2

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,581,440

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-061168 · doc4.xml · nonDerivative · entry 1

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,589,943

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.57 to $39.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-061274 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 248,380

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-061274 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.

SEC source: 0001209191-21-061274 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-059979 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-059853 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,755

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-059853 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.

SEC source: 0001209191-21-059853 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-058071 · doc4.xml · derivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,833

Underlying: Common Stock · 5,000 shares

Expires 2027-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-058071 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-057641 · doc4.xml · derivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,130

Underlying: Common Stock · 8,000 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-057641 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-057317 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259,130

Underlying: Common Stock · 4,125 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-057317 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.

SEC source: 0001209191-21-057317 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-057152 · doc4.xml · nonDerivative · entry 2

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,596,614

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.92 to $53.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-057152 · doc4.xml · nonDerivative · entry 1

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600,013

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.92 to $52.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-056602 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.282 to $50.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-056602 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,997

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-055311 · doc4.xml · derivative · entry 4

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,255

Underlying: Common Stock · 4,125 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-055311 · doc4.xml · nonDerivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.

SEC source: 0001209191-21-055311 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,450

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.

SEC source: 0001209191-21-055311 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 9

SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,739

SEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 8

SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 877,135

F6 · ownership.nature: The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.

SEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 7

SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 61,660

F5 · ownership.nature: The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.